Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to 400.59%.

  • Autolus Therapeutics' EBITDA Margin changed N/A to 400.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 447.55%, marking a year-over-year increase of 19022600.0%. This contributed to the annual value of 2182.25% for FY2024, which is 95066200.0% up from last year.
  • As of Q3 2025, Autolus Therapeutics' EBITDA Margin stood at 400.59%.
  • Autolus Therapeutics' 5-year EBITDA Margin high stood at 11893.31% for Q1 2021, and its period low was 192696.55% during Q4 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 589.51% (2024), whereas its average is 18966.25%.
  • In the last 5 years, Autolus Therapeutics' EBITDA Margin plummeted by -387107800bps in 2022 and then surged by 241727300bps in 2023.
  • Autolus Therapeutics' EBITDA Margin (Quarter) stood at 17.14% in 2021, then plummeted by -3015bps to 499.73% in 2022, then crashed by -2448bps to 12730.54% in 2023, then crashed by -1414bps to 192696.55% in 2024, then surged by 100bps to 400.59% in 2025.
  • Its last three reported values are 400.59% in Q3 2025, 138.36% for Q2 2025, and 657.9% during Q1 2025.